Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

New study compares Wegovy and Zepbound

The Mercury News · 3d
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.
U.S. News & World Report · 3d
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said. Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.
Associated Press News on MSN · 54m
CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
4don MSN
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
3d
Why patients are being forced to switch to a 2nd-choice obesity drug
CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...
1d
Tufts Health Plan, Harvard Pilgrim owner to limit coverage of weight-loss drugs
Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics

Wegovy
Novo Nordisk
Weight loss
Eli Lilly
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy